- SAN DIEGO, CA, September 10, 2008 — Synaptamine, Inc. Kenneth Blum, PhD, a renowned neuroscientist credited with the co-discovery (with Dr. Ernest Noble of UCLA and former director of The National Institute on Alcoholism and Alcohol Abuse (NIAAA)) of the first genetic association of the dopamine D2 receptor gene with severe alcoholism, resigned from Salugen earlier this year due to the company's inability to perform. All other key executives of the company, with the exception of Brian Meshkin, CEO, also resigned. In accordance with Dr. Blum's agreement with Salugen, all rights to the intellectual property portfolio primarily owned by Dr. Blum and his research associates reverted to Dr. Blum, principal of Synaptamine, Inc. and other named patent holders. Key factors in the departure of the management team were not specifically disclosed however, under Mr. Meshkin's direction, Salugen was unable to raise capital, adequately perform operational activities or compensate employees and vendors.
The Blum Intellectual Property portfolio consisting of both nutrigenomic, nutrigenetic and pharmacogenomic concepts, including those related to Reward Deficiency Syndrome (RDS), a term first coined by Blum in 1995, and patents issued and pending thereof in the United States, Europe and other countries, immediately reverted to Dr. Blum, Synaptamine, Inc. and associates upon his resignation and written recognition of the breech of contractual obligations by Salugen and Mr. Meshkin. The loss of these rights negates any claims by Salugen, its successor companies or Mr. Meshkin to the resultant products in the Salugen product portfolio or any other current or future products incorporating patented concepts.---
Press release service and press release distribution provided by http://www.24-7pressrelease.com
# # #